Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS raises approximately 2.2 million euros in a placement reserved to a category of persons 

11/07/2019
Dowload PDF File (615 Ko)

THERANEXUS announces the launch of a capital increase by private placement for a maximum amount of euro 4 million

10/07/2019
Download PDF File (284 Ko)

THERANEXUS reports cash position as of June 30th 2019

08/07/2019
Download PDF File (268 Ko)

Theranexus and Beyond Batten Disease Foundation (BBDF) announce agreement in
principle to develop and market Batten disease drug candidate BBDF 101

27/06/2019
Download PDF File (416 Ko)

THERANEXUS invited to join in the HealthTech Investor Days (HTDI) 24 & 25 June in Paris

20/06/2019
Download PDF File (363 Ko)

December, 2019 : CF&B Midcap Event, Geneva (exact date to be confirmed)

October 14 & 15, 2019 : CF&B European MidCap Event, Paris

September 20, 2019 : CF&B Midcap Event, Amsterdam